Form SD - Specialized disclosure report
28 Mai 2024 - 10:15PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM SD
Specialized Disclosure Report
Elanco
Animal Health Incorporated
(Exact name of registrant as specified
in its charter)
|
Indiana
(State or other jurisdiction
of incorporation)
|
|
001-38661
(Commission file number) |
2500 Innovation Way,
Greenfield Indiana
(Address of principal executive offices) |
|
46140
(Zip code) |
Shiv O’Neill
Executive Vice President, General Counsel and
Corporate Secretary
(877) 352-6261
(Name and telephone number, including area code,
of the person to contact in connection with this report.)
Check the appropriate box to indicate the rule pursuant to which this
form is being filed:
x |
Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2023. |
¨ |
Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended . |
Section 1 – Conflict Minerals
Disclosure
Items 1.01 and 1.02 Conflict Minerals Disclosure and Report, Exhibit
Conflict Minerals Disclosure
As required by Rule 13p-1 (the “Rule”), Elanco Animal Health
Incorporated (the “Company”) identified the following products that were potentially within the scope of the Rule for the
year ended December 31, 2023: BEAPHAR FLEA PREVENTION SPRAY 250ML, Bolfo Spray, Maxitrol, Milbemite, Nevanec, Tobradex and Tobrex (the
“Covered Products”).
The Covered Products were provided to the Company by a number of contract
manufacturers and suppliers. The Company conducted a conflict minerals reasonable country of origin inquiry (“RCOI”) for the
year ended December 31, 2023 but was unable to obtain documentation from some of the relevant suppliers on whether these products contain
tin, tungsten, tantalum or gold (the “3TG Minerals”), or if relevant, about the country of origin of any 3TG Minerals incorporated
into the products. As a result, the Company cannot rule out the possibility that these products contained 3TG Minerals originating in
the Democratic Republic of the Congo or an adjoining country (the “Covered Countries”).
The Company conducted its RCOI by identifying six contract manufacturers
and suppliers that may have provided components to the Company with 3TG Minerals which may have been used in the Covered Products during
the calendar year ended December 31, 2023 (the “Respondents”). The Company obtained information from the Respondents by requesting
responses to an internally developed questionnaire related to those components supplied to the Company to determine whether there were
any 3TG Materials contained in the components supplied to the Company and the country of origin of any 3TG Materials used in the Covered
Products (the “Supply Chain Questionnaire”).
The Company reviewed and analyzed the responses to the Supply Chain
Questionnaire. The Company received complete responses to the Supply Chain Questionnaire from four of six of the Respondents that it contacted.
Three of the Respondents indicated the products they provided to the Company were free of 3TG Minerals. One Respondent responded that
it was unable to determine if the products it supplied to the Company contained 3TG Minerals. One Respondent did not provide a complete
response to the Supply Chain Questionnaire but instead reported that, as part of the Respondent’s participation in the Responsible
Mineral Institute, it completes on an annual basis a Conflict Minerals Report Template under which it declares that any 3TG Minerals in
its products are sourced from smelters that participate in the Responsible Minerals Assurance Process. Despite the Company’s efforts
to follow up with the sixth Respondent, it did not complete the Supply Chain Questionnaire or provide any further information to the Company
about the products that it supplies to the Company to assist the Company in its compliance with the Rule. This particular Respondent supplied
materials for four of our Covered Products so the Company followed up with the vendor several times, but failed to receive useful information
as the Respondent reported that it is not directly subject to the Rule.
The Company believes the RCOI process that it followed for the calendar
year ended December 31, 2023 was performed in good faith and reasonably designed to determine whether any of the 3TG Minerals originated
in the Covered Countries or are from recycled or scrap sources. However, there are inherent limitations in the information provided by
third parties including potential inaccuracies and incompleteness or inaccurate information. The Company’s RCOI did not permit the
Company to determine whether any of the 3TG Materials used in the Covered Products during 2023 may have originated in a Covered Country.
Pursuant to the Public Statement issued by the SEC’s Division
of Corporate Finance on April 7, 2017, the Company has provided only the disclosure required under the provisions of paragraphs (a) and
(b) of Item 1.01 of Form SD and has not exercised due diligence in accordance with paragraph (c) of Item 1.01 of Form SD.
The information in this Form SD is publicly available on the Company’s
website at https://investor.elanco.com/financials/sec-filings/default.aspx; however, the information on the Company’s website
is not incorporated by reference into this Form SD and does not constitute a part of this Form SD.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
|
ELANCO ANIMAL HEALTH INCORPORATED |
|
(Registrant) |
|
|
|
By: |
/s/ Todd Young |
|
Name: |
Todd Young |
|
Title: |
Executive Vice President, Chief Financial Officer |
|
Date: |
May 28, 2024 |
Elanco Animal Health (NYSE:ELAN)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Elanco Animal Health (NYSE:ELAN)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024